Summary

The global Custom Radiolabeling and Radiosynthesis Services market is projected to grow from US$ 246 million in 2025 to US$ 424 million by 2032, at a CAGR of 8.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Custom Radiolabeling and Radiosynthesis Services refers to specialized radiochemistry services that design, synthesize, and deliver customer-specific radiolabeled compounds according to the target molecule, radioactive isotope, labeling position, and intended research application. Radioactive isotopes are selectively incorporated into drug candidates, active pharmaceutical ingredients, metabolites, agrochemicals, small molecules, peptides, proteins, antibodies, bioconjugates, oligonucleotides, and other target molecules through radiosynthesis, isotope exchange, tritiation, radioiodination, radiometal chelation, and other dedicated labeling techniques. These services typically encompass labeling-site design, radioactive precursor selection, synthetic route development and optimization, radiolabeling reactions, purification, chiral separation, radiochemical and chemical characterization, specific activity and purity control, stability management, storage, repurification, and controlled shipment, with both non-GMP and GMP material preparation available depending on project requirements. The resulting radiolabeled compounds are primarily used in pharmaceutical development and ADME studies, human mass-balance studies, pharmacokinetic and tissue-distribution studies, drug discovery and life-science research, agrochemical development and registration, chemical and environmental safety assessment, and radiopharmaceutical and molecular imaging development.
Key Findings
Carbon-14 custom synthesis remains the principal service type across pharmaceutical ADME, human mass-balance and agrochemical regulatory programs
Small molecules remain the largest target class while peptides, biologics and oligonucleotides are expanding the addressable radiolabeling market
Non-GMP projects form the broadest demand base while GMP radiosynthesis carries higher compliance requirements and project value
North America and Europe remain the principal radiochemistry service hubs while Asian suppliers continue expanding integrated synthesis and ADME capabilities
Competition combines large integrated CRO platforms with specialist radiochemistry companies differentiated by isotope expertise, molecule complexity and GMP capabilities
Market Trends
The market is shifting from conventional small-molecule carbon-14 and tritium synthesis toward more complex and integrated radiolabeled development programs. Customers increasingly expect suppliers to manage labeling-position selection, route redesign, radiosynthesis, purification, structural confirmation, release testing, storage and shipment as one coordinated workflow. This transition is particularly evident in new therapeutic modalities. Pharmaron now applies carbon-14 and tritium methods to peptides, proteins, antibodies, ADCs and oligonucleotides, while WuXi AppTec has extended customized radiolabeled synthesis to small molecules, PROTACs, XDCs and peptides. A second trend is the increasing integration of synthesis with downstream radiolabeled ADME, QWBA, metabolite identification and human mass-balance studies, allowing sponsors to reduce project transfers and maintain consistency in labeled material throughout development. At the same time, analytical requirements are becoming more sophisticated as complex molecules demand confirmation not only of radiochemical purity and specific activity but also of label position, molecular integrity and retained biological function. GMP capabilities are also becoming strategically more important as sponsors seek suppliers able to move a compound from discovery-grade material into clinical carbon-14 API and drug-product programs without rebuilding the radiochemistry supply chain.
Market Dynamics
Drivers
The principal demand driver is the continued importance of radiolabeled compounds in quantitative drug disposition and regulatory development. FDA guidance on human radiolabeled mass-balance studies describes these studies as a direct method for obtaining comprehensive information on drug absorption, distribution, metabolism and excretion and indicates that carbon-14 and tritium are commonly used labels. Agricultural regulation creates another durable demand base: OECD crop-metabolism guidance requires labeled active ingredients so that residues and degradation pathways can be quantified and traced, with carbon-14 identified as the preferred isotope in most cases. Outsourcing is further supported by the specialized nature of radiochemistry. Licensed radioactive-material facilities, experienced radiochemists, dedicated analytical infrastructure, radiation protection, radioactive-waste management and international dangerous-goods logistics create substantial barriers to building an internal platform, encouraging pharmaceutical, biotechnology and agrochemical companies to use specialist providers.
Restraints
Growth is restrained by limited availability and high cost of radioactive starting materials, the complexity of route design and the operational burden associated with radioactive-material handling. Carbon-14 projects often require redesigning a conventional synthesis around a limited selection of commercially available labeled building blocks, while tritium work may require dedicated gas-handling equipment, isotope-exchange chemistry or specialized reduction and methylation techniques. Multi-step radiosynthesis can also suffer from low overall recovery because valuable radioactivity is lost during reactions, purification and analytical sampling. In addition, radiolabeled materials may have distinct impurity and stability profiles compared with their unlabeled analogues, creating additional requirements for storage, monitoring and repurification. Clinical-grade programs add GMP documentation, release, stability and quality-system requirements, increasing both lead times and project costs. Eurofins, for example, operates dedicated cGMP synthesis suites because relatively few laboratories can support certified radiolabeled APIs for human studies.
Opportunities
The largest incremental opportunities are emerging from complex therapeutic modalities and higher-value integrated programs. Peptides, proteins, antibodies, bioconjugates and oligonucleotides increasingly require tailored radiolabeling strategies because their biological activity and structural integrity must be preserved after labeling. Pharmaron's current tritium platform explicitly covers nucleotides, oligonucleotides, peptides, proteins, antibodies and ADCs, illustrating how radiochemistry is expanding beyond conventional small molecules. Another opportunity lies in GMP carbon-14 materials for early clinical development and human mass-balance studies. Moravek, Eurofins, Pharmaron and Nuvisan have established dedicated GMP radiochemistry capabilities, demonstrating the commercial attractiveness of moving from research-grade custom synthesis into regulated clinical supply. Suppliers that can combine synthesis, radiochemical analysis, ADME, metabolite profiling and clinical-study support are positioned to capture a larger proportion of project value and establish longer customer relationships.
Challenges
The central scientific challenge is selecting a label position that remains representative of the parent molecule throughout the intended experiment. A poorly positioned carbon-14 or tritium label can be lost through metabolism or exchange, compromising interpretation of mass-balance, metabolism or tissue-distribution data. OECD guidance similarly emphasizes positioning the radiolabel so that significant molecular moieties and degradation products can be tracked. Biologics create an additional challenge because radioiodination, covalent tagging or radiometal conjugation can alter binding affinity, conformation or biological activity. Providers must therefore balance specific activity, radiochemical purity, chemical purity, biological integrity and stability. Other risks include radionuclide supply interruptions, radioactive decay and radiolysis, specialist talent shortages, regulatory differences between jurisdictions and constraints on international transport of radioactive materials. These factors favor experienced suppliers but can restrict capacity expansion and increase project scheduling risk.
Industry Chain Analysis
The upstream industry chain comprises radionuclides and radioactive precursors, unlabeled APIs and intermediates, specialty reagents, catalysts and chelators, analytical instrumentation, shielding and radiation-monitoring systems, radioactive-material packaging and licensed logistics. Carbon-14 projects depend heavily on access to suitable labeled building blocks, while tritium programs use tritium gas, tritiated water and specialized tritiated reagents; radioiodine and other radionuclides support more specialized peptide, protein and antibody programs. The midstream layer is the core value-creation stage and includes labeling-position strategy, route development, radiosynthesis, purification, analytical characterization, quality release, stability management, storage and shipment. High-value providers differentiate through synthetic success rates, isotope expertise, GMP infrastructure and the ability to solve complex labeling-position and purification problems. Downstream demand comes primarily from pharmaceutical and biotechnology developers, agrochemical companies and drug-discovery or life-science laboratories. Increasing integration between radiosynthesis and downstream ADME, QWBA, metabolite identification and clinical mass-balance studies is shifting more value toward service platforms that can manage the entire radiolabeled development workflow.
Segment Insights
By radionuclide, Carbon-14 Custom Synthesis represents the largest and most established segment because carbon-14 can be incorporated at defined structural positions and is suitable for pharmaceutical metabolism, human mass-balance, agrochemical metabolism and environmental-fate studies. OECD guidance specifically identifies carbon-14 as the preferred isotope for crop-metabolism studies, while FDA materials confirm the established use of carbon-14 in human radiolabeled mass-balance programs. Tritium Custom Synthesis forms the second major segment and is particularly valuable when high specific activity is required for pharmacology, receptor-binding and drug-discovery programs. Radioiodine Labeling serves a more specialized market centered on peptides, proteins, antibodies and radioligands, while Others covers sulfur, phosphorus, radiometals and other radionuclides used in specialized research or radiopharmaceutical development.
By target molecule, Small Molecules remain the largest commercial category because conventional drug candidates, APIs, metabolites and agrochemical active ingredients account for the majority of established radiosynthesis workflows. Peptides & Non-Antibody Proteins, Antibodies & Bioconjugates and Oligonucleotides & Nucleic Acids are gaining importance as pharmaceutical pipelines diversify. By regulatory and quality level, Non-GMP Custom Radiosynthesis represents the broader project base across discovery, nonclinical and regulatory research, while GMP Custom Radiosynthesis is a smaller but higher-value segment centered on clinical-grade radiolabeled API and drug-product preparation. Eurofins maintains four dedicated cGMP synthesis suites, while Moravek reports more than two thousand carbon-14 custom syntheses and a substantial history of GMP carbon-14 API production, illustrating the technical barriers and accumulated expertise required in this segment.
Downstream Market Opportunities
Pharmaceutical Development & ADME Studies constitute the largest downstream opportunity because radiolabeled materials support nonclinical disposition studies, metabolite profiling, tissue distribution, human mass balance and clinical pharmacology. FDA's current guidance continues to reinforce the role of human radiolabeled mass-balance studies in development of new molecular entities. Agrochemical Development & Registration provides a mature but resilient demand base because labeled active ingredients remain necessary for tracking crop metabolism, residues and degradation pathways under established regulatory frameworks. Drug Discovery & Life Science Research generates recurring demand for high-specific-activity tracers used in receptor, transporter, enzyme, cellular and target-engagement studies, particularly through tritium and radioiodine labeling. The most attractive incremental opportunity is increasingly the combination of complex-molecule labeling with integrated downstream research, enabling customers to procure synthesis, characterization and biological or clinical study execution through a smaller number of qualified suppliers.
Regional Insights
North America and Europe remain the principal global hubs for Custom Radiolabeling and Radiosynthesis Services because they combine mature pharmaceutical R&D ecosystems with long-established radiochemistry infrastructure and specialist suppliers. North America has substantial capabilities through Revvity, Labcorp, Moravek, American Radiolabeled Chemicals, Charles River, ViTrax and AM Chemicals, while Europe has a particularly dense specialist base spanning Eurofins Scientific, Quotient Sciences, Almac Group, Nuvisan, Institute of Isotopes, Hartmann Analytic, Chelatec, Eckert & Ziegler, RC Tritec and Novandi Chemistry. Europe's strength extends from carbon-14 and tritium chemistry to GMP radiolabeled APIs and radioconjugate development, with established links to pharmaceutical, agrochemical and radiopharmaceutical regulatory programs.
Asia is developing a broader regional supply network. China now has integrated capabilities through Pharmaron, WuXi AppTec, Frontage Laboratories, JOINN Laboratories and Medicilon, alongside specialist companies such as Zhejiang Isotope Labelled Compounds and Wuxi Beita Pharmatech. Japan retains an established position through Sekisui Medical, while South Korea has developed dedicated carbon-14 capability through Curachem. Expansion of Asian capacity is improving local access to isotope chemistry, shortening project interfaces with regional ADME laboratories and gradually reducing dependence on imported labeled materials for domestic pharmaceutical development.
Competitive Landscape Analysis
Competition combines large integrated CRO and CDMO platforms with highly specialized radiochemistry companies. Pharmaron, Eurofins Scientific, WuXi AppTec, Quotient Sciences, Revvity, Labcorp, Almac Group, Nuvisan and Sekisui Medical compete through broader development platforms and the ability to link radiosynthesis with analytical, ADME or clinical services, while Moravek, Institute of Isotopes, Curachem, American Radiolabeled Chemicals, Hartmann Analytic, Chelatec, ViTrax, RC Tritec, Novandi Chemistry, AptoChem and AM Chemicals differentiate through deeper specialization in selected isotopes or molecule classes. Eckert & Ziegler and Charles River extend competition into radioconjugates, radiopharmaceutical development and molecular-imaging-oriented labeling. Competitive advantage increasingly depends on radiochemist expertise, access to radioactive precursors, successful labeling-site and route design, analytical depth, GMP qualification, turnaround time and international shipping capability.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Custom Radiolabeling and Radiosynthesis Services market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Eurofins Scientific
Moravek
Quotient Sciences
Revvity
Labcorp
Almac Group
Nuvisan
Sekisui Medical
Institute of Isotopes
Curachem
American Radiolabeled Chemicals
Hartmann Analytic
Chelatec
Eckert & Ziegler
Charles River
ViTrax
RC Tritec
Novandi Chemistry
AptoChem
PolyPeptide
AM Chemicals
Pharmaron
WuXi AppTec
Frontage Laboratories
JOINN Laboratories
Zhejiang Isotope Labelled Compounds
Medicilon
Wuxi Beita Pharmatech
Segment by Type
Carbon-14 Custom Synthesis
Tritium Custom Synthesis
Radioiodine Labeling
Others
Segment by Target Molecule
Small Molecules
Peptides & Non-Antibody Proteins
Antibodies & Bioconjugates
Oligonucleotides & Nucleic Acids
Others
Segment by Regulatory and Quality Level
Non-GMP Custom Radiosynthesis
GMP Custom Radiosynthesis
Segment by Application
Pharmaceutical Development & ADME Studies
Agrochemical Development & Registration
Drug Discovery & Life Science Research
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Custom Radiolabeling and Radiosynthesis Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Custom Radiolabeling and Radiosynthesis Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Custom Radiolabeling and Radiosynthesis Services Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Carbon-14 Custom Synthesis
1.2.3 Tritium Custom Synthesis
1.2.4 Radioiodine Labeling
1.2.5 Others
1.3 Market Segmentation by Target Molecule
1.3.1 Global Custom Radiolabeling and Radiosynthesis Services Market Size by Target Molecule, 2021 vs 2025 vs 2032
1.3.2 Small Molecules
1.3.3 Peptides & Non-Antibody Proteins
1.3.4 Antibodies & Bioconjugates
1.3.5 Oligonucleotides & Nucleic Acids
1.3.6 Others
1.4 Market Segmentation by Regulatory and Quality Level
1.4.1 Global Custom Radiolabeling and Radiosynthesis Services Market Size by Regulatory and Quality Level, 2021 vs 2025 vs 2032
1.4.2 Non-GMP Custom Radiosynthesis
1.4.3 GMP Custom Radiosynthesis
1.5 Market Segmentation by Application
1.5.1 Global Custom Radiolabeling and Radiosynthesis Services Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical Development & ADME Studies
1.5.3 Agrochemical Development & Registration
1.5.4 Drug Discovery & Life Science Research
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Custom Radiolabeling and Radiosynthesis Services Revenue Estimates and Forecasts (2021-2032)
2.2 Global Custom Radiolabeling and Radiosynthesis Services Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Custom Radiolabeling and Radiosynthesis Services Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Custom Radiolabeling and Radiosynthesis Services Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Carbon-14 Custom Synthesis: Market Share by Key Players
3.3.2 Tritium Custom Synthesis: Market Share by Key Players
3.3.3 Radioiodine Labeling: Market Share by Key Players
3.3.4 Others: Market Share by Key Players
3.4 Global Custom Radiolabeling and Radiosynthesis Services Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Custom Radiolabeling and Radiosynthesis Services Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Custom Radiolabeling and Radiosynthesis Services Market by Target Molecule
4.2.1 Global Revenue by Target Molecule (2021-2032)
4.2.2 Global Revenue-Based Market Share by Target Molecule (2021-2032)
4.3 Global Custom Radiolabeling and Radiosynthesis Services Market by Regulatory and Quality Level
4.3.1 Global Revenue by Regulatory and Quality Level (2021-2032)
4.3.2 Global Revenue-Based Market Share by Regulatory and Quality Level (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Custom Radiolabeling and Radiosynthesis Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Custom Radiolabeling and Radiosynthesis Services Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Custom Radiolabeling and Radiosynthesis Services Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Custom Radiolabeling and Radiosynthesis Services Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Custom Radiolabeling and Radiosynthesis Services Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Custom Radiolabeling and Radiosynthesis Services Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Custom Radiolabeling and Radiosynthesis Services Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Eurofins Scientific
11.1.1 Eurofins Scientific Corporation Information
11.1.2 Eurofins Scientific Business Overview
11.1.3 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.1.4 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.1.5 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services Revenue by Product in 2025
11.1.6 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services Revenue by Application in 2025
11.1.7 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services Revenue by Geographic Area in 2025
11.1.8 Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
11.1.9 Eurofins Scientific Recent Developments
11.2 Moravek
11.2.1 Moravek Corporation Information
11.2.2 Moravek Business Overview
11.2.3 Moravek Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.2.4 Moravek Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.2.5 Moravek Custom Radiolabeling and Radiosynthesis Services Revenue by Product in 2025
11.2.6 Moravek Custom Radiolabeling and Radiosynthesis Services Revenue by Application in 2025
11.2.7 Moravek Custom Radiolabeling and Radiosynthesis Services Revenue by Geographic Area in 2025
11.2.8 Moravek Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
11.2.9 Moravek Recent Developments
11.3 Quotient Sciences
11.3.1 Quotient Sciences Corporation Information
11.3.2 Quotient Sciences Business Overview
11.3.3 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.3.4 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.3.5 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services Revenue by Product in 2025
11.3.6 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services Revenue by Application in 2025
11.3.7 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services Revenue by Geographic Area in 2025
11.3.8 Quotient Sciences Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
11.3.9 Quotient Sciences Recent Developments
11.4 Revvity
11.4.1 Revvity Corporation Information
11.4.2 Revvity Business Overview
11.4.3 Revvity Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.4.4 Revvity Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.4.5 Revvity Custom Radiolabeling and Radiosynthesis Services Revenue by Product in 2025
11.4.6 Revvity Custom Radiolabeling and Radiosynthesis Services Revenue by Application in 2025
11.4.7 Revvity Custom Radiolabeling and Radiosynthesis Services Revenue by Geographic Area in 2025
11.4.8 Revvity Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
11.4.9 Revvity Recent Developments
11.5 Labcorp
11.5.1 Labcorp Corporation Information
11.5.2 Labcorp Business Overview
11.5.3 Labcorp Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.5.4 Labcorp Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.5.5 Labcorp Custom Radiolabeling and Radiosynthesis Services Revenue by Product in 2025
11.5.6 Labcorp Custom Radiolabeling and Radiosynthesis Services Revenue by Application in 2025
11.5.7 Labcorp Custom Radiolabeling and Radiosynthesis Services Revenue by Geographic Area in 2025
11.5.8 Labcorp Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
11.5.9 Labcorp Recent Developments
11.6 Almac Group
11.6.1 Almac Group Corporation Information
11.6.2 Almac Group Business Overview
11.6.3 Almac Group Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.6.4 Almac Group Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.6.5 Almac Group Recent Developments
11.7 Nuvisan
11.7.1 Nuvisan Corporation Information
11.7.2 Nuvisan Business Overview
11.7.3 Nuvisan Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.7.4 Nuvisan Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.7.5 Nuvisan Recent Developments
11.8 Sekisui Medical
11.8.1 Sekisui Medical Corporation Information
11.8.2 Sekisui Medical Business Overview
11.8.3 Sekisui Medical Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.8.4 Sekisui Medical Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.8.5 Sekisui Medical Recent Developments
11.9 Institute of Isotopes
11.9.1 Institute of Isotopes Corporation Information
11.9.2 Institute of Isotopes Business Overview
11.9.3 Institute of Isotopes Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.9.4 Institute of Isotopes Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.9.5 Institute of Isotopes Recent Developments
11.10 Curachem
11.10.1 Curachem Corporation Information
11.10.2 Curachem Business Overview
11.10.3 Curachem Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.10.4 Curachem Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 American Radiolabeled Chemicals
11.11.1 American Radiolabeled Chemicals Corporation Information
11.11.2 American Radiolabeled Chemicals Business Overview
11.11.3 American Radiolabeled Chemicals Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.11.4 American Radiolabeled Chemicals Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.11.5 American Radiolabeled Chemicals Recent Developments
11.12 Hartmann Analytic
11.12.1 Hartmann Analytic Corporation Information
11.12.2 Hartmann Analytic Business Overview
11.12.3 Hartmann Analytic Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.12.4 Hartmann Analytic Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.12.5 Hartmann Analytic Recent Developments
11.13 Chelatec
11.13.1 Chelatec Corporation Information
11.13.2 Chelatec Business Overview
11.13.3 Chelatec Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.13.4 Chelatec Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.13.5 Chelatec Recent Developments
11.14 Eckert & Ziegler
11.14.1 Eckert & Ziegler Corporation Information
11.14.2 Eckert & Ziegler Business Overview
11.14.3 Eckert & Ziegler Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.14.4 Eckert & Ziegler Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.14.5 Eckert & Ziegler Recent Developments
11.15 Charles River
11.15.1 Charles River Corporation Information
11.15.2 Charles River Business Overview
11.15.3 Charles River Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.15.4 Charles River Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.15.5 Charles River Recent Developments
11.16 ViTrax
11.16.1 ViTrax Corporation Information
11.16.2 ViTrax Business Overview
11.16.3 ViTrax Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.16.4 ViTrax Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.16.5 ViTrax Recent Developments
11.17 RC Tritec
11.17.1 RC Tritec Corporation Information
11.17.2 RC Tritec Business Overview
11.17.3 RC Tritec Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.17.4 RC Tritec Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.17.5 RC Tritec Recent Developments
11.18 Novandi Chemistry
11.18.1 Novandi Chemistry Corporation Information
11.18.2 Novandi Chemistry Business Overview
11.18.3 Novandi Chemistry Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.18.4 Novandi Chemistry Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.18.5 Novandi Chemistry Recent Developments
11.19 AptoChem
11.19.1 AptoChem Corporation Information
11.19.2 AptoChem Business Overview
11.19.3 AptoChem Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.19.4 AptoChem Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.19.5 AptoChem Recent Developments
11.20 PolyPeptide
11.20.1 PolyPeptide Corporation Information
11.20.2 PolyPeptide Business Overview
11.20.3 PolyPeptide Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.20.4 PolyPeptide Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.20.5 PolyPeptide Recent Developments
11.21 AM Chemicals
11.21.1 AM Chemicals Corporation Information
11.21.2 AM Chemicals Business Overview
11.21.3 AM Chemicals Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.21.4 AM Chemicals Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.21.5 AM Chemicals Recent Developments
11.22 Pharmaron
11.22.1 Pharmaron Corporation Information
11.22.2 Pharmaron Business Overview
11.22.3 Pharmaron Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.22.4 Pharmaron Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.22.5 Pharmaron Recent Developments
11.23 WuXi AppTec
11.23.1 WuXi AppTec Corporation Information
11.23.2 WuXi AppTec Business Overview
11.23.3 WuXi AppTec Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.23.4 WuXi AppTec Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.23.5 WuXi AppTec Recent Developments
11.24 Frontage Laboratories
11.24.1 Frontage Laboratories Corporation Information
11.24.2 Frontage Laboratories Business Overview
11.24.3 Frontage Laboratories Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.24.4 Frontage Laboratories Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.24.5 Frontage Laboratories Recent Developments
11.25 JOINN Laboratories
11.25.1 JOINN Laboratories Corporation Information
11.25.2 JOINN Laboratories Business Overview
11.25.3 JOINN Laboratories Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.25.4 JOINN Laboratories Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.25.5 JOINN Laboratories Recent Developments
11.26 Zhejiang Isotope Labelled Compounds
11.26.1 Zhejiang Isotope Labelled Compounds Corporation Information
11.26.2 Zhejiang Isotope Labelled Compounds Business Overview
11.26.3 Zhejiang Isotope Labelled Compounds Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.26.4 Zhejiang Isotope Labelled Compounds Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.26.5 Zhejiang Isotope Labelled Compounds Recent Developments
11.27 Medicilon
11.27.1 Medicilon Corporation Information
11.27.2 Medicilon Business Overview
11.27.3 Medicilon Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.27.4 Medicilon Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.27.5 Medicilon Recent Developments
11.28 Wuxi Beita Pharmatech
11.28.1 Wuxi Beita Pharmatech Corporation Information
11.28.2 Wuxi Beita Pharmatech Business Overview
11.28.3 Wuxi Beita Pharmatech Custom Radiolabeling and Radiosynthesis Services Product Features and Attributes
11.28.4 Wuxi Beita Pharmatech Custom Radiolabeling and Radiosynthesis Services Revenue and Gross Margin (2021-2026)
11.28.5 Wuxi Beita Pharmatech Recent Developments

12 Custom Radiolabeling and Radiosynthesis Services Value Chain and Ecosystem Analysis
12.1 Custom Radiolabeling and Radiosynthesis Services Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Custom Radiolabeling and Radiosynthesis Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Custom Radiolabeling and Radiosynthesis Services Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Target Molecule, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Regulatory and Quality Level, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Region (US$ Million), 2021-2026
Table 7. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Players (US$ Million), 2021-2026
Table 10. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Custom Radiolabeling and Radiosynthesis Services Revenue, 2025
Table 13. Global Custom Radiolabeling and Radiosynthesis Services Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Custom Radiolabeling and Radiosynthesis Services Companies Headquarters
Table 15. Global Custom Radiolabeling and Radiosynthesis Services Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Type (US$ Million), 2021-2026
Table 19. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Type (US$ Million), 2027-2032
Table 20. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Target Molecule (US$ Million), 2021-2026
Table 21. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Target Molecule (US$ Million), 2027-2032
Table 22. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Regulatory and Quality Level (US$ Million), 2021-2026
Table 23. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Regulatory and Quality Level (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Application (US$ Million), 2021-2026
Table 26. Global Custom Radiolabeling and Radiosynthesis Services Revenue by Application (US$ Million), 2027-2032
Table 27. Custom Radiolabeling and Radiosynthesis Services High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Custom Radiolabeling and Radiosynthesis Services Growth Accelerators and Market Barriers
Table 31. North America Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Custom Radiolabeling and Radiosynthesis Services Growth Accelerators and Market Barriers
Table 33. Europe Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Custom Radiolabeling and Radiosynthesis Services Investment Opportunities and Key Challenges
Table 37. Central and South America Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Eurofins Scientific Corporation Information
Table 41. Eurofins Scientific Description and Major Businesses
Table 42. Eurofins Scientific Product Features and Attributes
Table 43. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Eurofins Scientific Revenue Proportion by Product in 2025
Table 45. Eurofins Scientific Revenue Proportion by Application in 2025
Table 46. Eurofins Scientific Revenue Proportion by Geographic Area in 2025
Table 47. Eurofins Scientific Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
Table 48. Eurofins Scientific Recent Developments
Table 49. Moravek Corporation Information
Table 50. Moravek Description and Major Businesses
Table 51. Moravek Product Features and Attributes
Table 52. Moravek Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Moravek Revenue Proportion by Product in 2025
Table 54. Moravek Revenue Proportion by Application in 2025
Table 55. Moravek Revenue Proportion by Geographic Area in 2025
Table 56. Moravek Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
Table 57. Moravek Recent Developments
Table 58. Quotient Sciences Corporation Information
Table 59. Quotient Sciences Description and Major Businesses
Table 60. Quotient Sciences Product Features and Attributes
Table 61. Quotient Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Quotient Sciences Revenue Proportion by Product in 2025
Table 63. Quotient Sciences Revenue Proportion by Application in 2025
Table 64. Quotient Sciences Revenue Proportion by Geographic Area in 2025
Table 65. Quotient Sciences Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
Table 66. Quotient Sciences Recent Developments
Table 67. Revvity Corporation Information
Table 68. Revvity Description and Major Businesses
Table 69. Revvity Product Features and Attributes
Table 70. Revvity Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Revvity Revenue Proportion by Product in 2025
Table 72. Revvity Revenue Proportion by Application in 2025
Table 73. Revvity Revenue Proportion by Geographic Area in 2025
Table 74. Revvity Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
Table 75. Revvity Recent Developments
Table 76. Labcorp Corporation Information
Table 77. Labcorp Description and Major Businesses
Table 78. Labcorp Product Features and Attributes
Table 79. Labcorp Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Labcorp Revenue Proportion by Product in 2025
Table 81. Labcorp Revenue Proportion by Application in 2025
Table 82. Labcorp Revenue Proportion by Geographic Area in 2025
Table 83. Labcorp Custom Radiolabeling and Radiosynthesis Services SWOT Analysis
Table 84. Labcorp Recent Developments
Table 85. Almac Group Corporation Information
Table 86. Almac Group Description and Major Businesses
Table 87. Almac Group Product Features and Attributes
Table 88. Almac Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Almac Group Recent Developments
Table 90. Nuvisan Corporation Information
Table 91. Nuvisan Description and Major Businesses
Table 92. Nuvisan Product Features and Attributes
Table 93. Nuvisan Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Nuvisan Recent Developments
Table 95. Sekisui Medical Corporation Information
Table 96. Sekisui Medical Description and Major Businesses
Table 97. Sekisui Medical Product Features and Attributes
Table 98. Sekisui Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Sekisui Medical Recent Developments
Table 100. Institute of Isotopes Corporation Information
Table 101. Institute of Isotopes Description and Major Businesses
Table 102. Institute of Isotopes Product Features and Attributes
Table 103. Institute of Isotopes Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Institute of Isotopes Recent Developments
Table 105. Curachem Corporation Information
Table 106. Curachem Description and Major Businesses
Table 107. Curachem Product Features and Attributes
Table 108. Curachem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Curachem Recent Developments
Table 110. American Radiolabeled Chemicals Corporation Information
Table 111. American Radiolabeled Chemicals Description and Major Businesses
Table 112. American Radiolabeled Chemicals Product Features and Attributes
Table 113. American Radiolabeled Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. American Radiolabeled Chemicals Recent Developments
Table 115. Hartmann Analytic Corporation Information
Table 116. Hartmann Analytic Description and Major Businesses
Table 117. Hartmann Analytic Product Features and Attributes
Table 118. Hartmann Analytic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hartmann Analytic Recent Developments
Table 120. Chelatec Corporation Information
Table 121. Chelatec Description and Major Businesses
Table 122. Chelatec Product Features and Attributes
Table 123. Chelatec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Chelatec Recent Developments
Table 125. Eckert & Ziegler Corporation Information
Table 126. Eckert & Ziegler Description and Major Businesses
Table 127. Eckert & Ziegler Product Features and Attributes
Table 128. Eckert & Ziegler Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Eckert & Ziegler Recent Developments
Table 130. Charles River Corporation Information
Table 131. Charles River Description and Major Businesses
Table 132. Charles River Product Features and Attributes
Table 133. Charles River Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Charles River Recent Developments
Table 135. ViTrax Corporation Information
Table 136. ViTrax Description and Major Businesses
Table 137. ViTrax Product Features and Attributes
Table 138. ViTrax Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. ViTrax Recent Developments
Table 140. RC Tritec Corporation Information
Table 141. RC Tritec Description and Major Businesses
Table 142. RC Tritec Product Features and Attributes
Table 143. RC Tritec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. RC Tritec Recent Developments
Table 145. Novandi Chemistry Corporation Information
Table 146. Novandi Chemistry Description and Major Businesses
Table 147. Novandi Chemistry Product Features and Attributes
Table 148. Novandi Chemistry Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Novandi Chemistry Recent Developments
Table 150. AptoChem Corporation Information
Table 151. AptoChem Description and Major Businesses
Table 152. AptoChem Product Features and Attributes
Table 153. AptoChem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AptoChem Recent Developments
Table 155. PolyPeptide Corporation Information
Table 156. PolyPeptide Description and Major Businesses
Table 157. PolyPeptide Product Features and Attributes
Table 158. PolyPeptide Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. PolyPeptide Recent Developments
Table 160. AM Chemicals Corporation Information
Table 161. AM Chemicals Description and Major Businesses
Table 162. AM Chemicals Product Features and Attributes
Table 163. AM Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. AM Chemicals Recent Developments
Table 165. Pharmaron Corporation Information
Table 166. Pharmaron Description and Major Businesses
Table 167. Pharmaron Product Features and Attributes
Table 168. Pharmaron Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Pharmaron Recent Developments
Table 170. WuXi AppTec Corporation Information
Table 171. WuXi AppTec Description and Major Businesses
Table 172. WuXi AppTec Product Features and Attributes
Table 173. WuXi AppTec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi AppTec Recent Developments
Table 175. Frontage Laboratories Corporation Information
Table 176. Frontage Laboratories Description and Major Businesses
Table 177. Frontage Laboratories Product Features and Attributes
Table 178. Frontage Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Frontage Laboratories Recent Developments
Table 180. JOINN Laboratories Corporation Information
Table 181. JOINN Laboratories Description and Major Businesses
Table 182. JOINN Laboratories Product Features and Attributes
Table 183. JOINN Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. JOINN Laboratories Recent Developments
Table 185. Zhejiang Isotope Labelled Compounds Corporation Information
Table 186. Zhejiang Isotope Labelled Compounds Description and Major Businesses
Table 187. Zhejiang Isotope Labelled Compounds Product Features and Attributes
Table 188. Zhejiang Isotope Labelled Compounds Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Zhejiang Isotope Labelled Compounds Recent Developments
Table 190. Medicilon Corporation Information
Table 191. Medicilon Description and Major Businesses
Table 192. Medicilon Product Features and Attributes
Table 193. Medicilon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Medicilon Recent Developments
Table 195. Wuxi Beita Pharmatech Corporation Information
Table 196. Wuxi Beita Pharmatech Description and Major Businesses
Table 197. Wuxi Beita Pharmatech Product Features and Attributes
Table 198. Wuxi Beita Pharmatech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Wuxi Beita Pharmatech Recent Developments
Table 200. Technologies, Platforms and Infrastructure
Table 201. Distributors List
Table 202. Market Trends and Market Evolution
Table 203. Market Drivers and Opportunities
Table 204. Market Challenges, Risks, and Restraints
Table 205. Research Programs/Design for This Report
Table 206. Key Data Information from Secondary Sources
Table 207. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Carbon-14 Custom Synthesis Product Picture
Figure 3. Tritium Custom Synthesis Product Picture
Figure 4. Radioiodine Labeling Product Picture
Figure 5. Others Product Picture
Figure 6. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Target Molecule, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Small Molecules Product Picture
Figure 8. Peptides & Non-Antibody Proteins Product Picture
Figure 9. Antibodies & Bioconjugates Product Picture
Figure 10. Oligonucleotides & Nucleic Acids Product Picture
Figure 11. Others Product Picture
Figure 12. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Regulatory and Quality Level, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Non-GMP Custom Radiosynthesis Product Picture
Figure 14. GMP Custom Radiosynthesis Product Picture
Figure 15. Global Custom Radiolabeling and Radiosynthesis Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pharmaceutical Development & ADME Studies
Figure 17. Agrochemical Development & Registration
Figure 18. Drug Discovery & Life Science Research
Figure 19. Others
Figure 20. Custom Radiolabeling and Radiosynthesis Services Report Years Considered
Figure 21. Global Custom Radiolabeling and Radiosynthesis Services Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 23. Global Custom Radiolabeling and Radiosynthesis Services Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share Ranking (2025)
Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 27. Carbon-14 Custom Synthesis Revenue-Based Market Share by Player in 2025
Figure 28. Tritium Custom Synthesis Revenue-Based Market Share by Player in 2025
Figure 29. Radioiodine Labeling Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Target Molecule (2021-2032)
Figure 33. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Regulatory and Quality Level (2021-2032)
Figure 34. Global Custom Radiolabeling and Radiosynthesis Services Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Custom Radiolabeling and Radiosynthesis Services Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) in 2025
Figure 37. North America Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 39. Canada Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 40. Mexico Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 41. Europe Custom Radiolabeling and Radiosynthesis Services Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) in 2025
Figure 43. Europe Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 45. France Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 46. U.K. Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 47. Italy Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 48. Russia Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 53. Japan Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 54. South Korea Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 55. Australia Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 56. India Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 60. Philippines Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 61. Singapore Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Custom Radiolabeling and Radiosynthesis Services Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) in 2025
Figure 64. Central and South America Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 66. Argentina Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 71. Israel Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 72. Egypt Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 73. South Africa Custom Radiolabeling and Radiosynthesis Services Revenue (US$ Million), 2021-2032
Figure 74. Custom Radiolabeling and Radiosynthesis Services Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed